SCUBE2: A Potential Drug Target and Biomarker (G57758)

Target Name: SCUBE2

NCBI ID: G57758

SCUBE2: A Potential Drug Target and Biomarker

Scubue2 (Signal peptide, CUB and EGF-like domain-containing protein 2) is a protein that has been identified as a potential drug target and biomarker. It is a member of the SCUBA (secretory signal-transduction adaptor) family, which is involved in the intracellular signaling pathway known as the TGF-β pathway. The TGF-β pathway is a critical pathway that regulates cell growth, differentiation, and survival, and is implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The SCUBA family has been identified as a potential drug target due to its involvement in the TGF-β pathway and its ability to regulate the activity of various signaling pathways, including the TGF-β pathway. The TGF-β pathway is known for its role in the development and maintenance of tissues, and is involved in the regulation of cell proliferation, differentiation, and survival. It is also implicated in the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Scubue2 is a protein that is expressed in a variety of tissues and cells, including neurons, glial cells, and immune cells. It is involved in the regulation of the TGF-β pathway and has been shown to play a role in the development and maintenance of tissues.

In addition to its involvement in the TGF-β pathway, Scubue2 has also been shown to be involved in the regulation of other signaling pathways, including the PI3K/Akt signaling pathway and the NF-kappa-B signaling pathway. The PI3K/Akt signaling pathway is involved in the regulation of cell survival and growth, and is implicated in the development of various diseases, including cancer. The NF-kappa-B signaling pathway is involved in the regulation of inflammation and immune responses, and is implicated in the development of autoimmune disorders.

Scubue2 has also been shown to be involved in the regulation of the cytoskeleton, which is the structure that organizes and supports cells. The cytoskeleton is involved in the regulation of cell movement and the maintenance of cell shape, and is implicated in the development of various diseases, including cancer.

In conclusion, Scubue2 is a protein that is involved in the regulation of several signaling pathways, including the TGF-β pathway, the PI3K/Akt signaling pathway, the NF-kappa-B signaling pathway, and the cytoskeleton. It is a potential drug target and biomarker due to its involvement in the development and maintenance of tissues and its ability to regulate the activity of various signaling pathways. Further research is needed to fully understand the role of Scubue2 in the regulation of tissues and the development of diseases.

Targeting Scubue2 as a drug target

The identification of a potential drug target is an important step in the development of new treatments for various diseases. The SCUBA family, including Scubue2, has been identified as a potential drug target due to its involvement in the TGF-β pathway and its ability to regulate the activity of various signaling pathways.

Scubue2 can be targeted using small molecules, such as inhibitors, or antibodies that specifically bind to its unique and conserved domains. These small molecules can then inhibit the activity of Scubue2 and disrupt its ability to regulate the TGF-β pathway and other signaling pathways.

One approach to targeting Scubue2 is to use inhibitors of the PI3K/Akt signaling pathway, which is known to be involved in the regulation of cell survival and growth. Activating the PI3K/Akt signaling pathway can lead to the development of various diseases, including cancer. By inhibiting this pathway, Scubue2's activity

Protein Name: Signal Peptide, CUB Domain And EGF Like Domain Containing 2

Functions: Lipid-binding protein required for SHH long-range signaling by binding to the dually lipid-modified SHH (ShhNp) and by promoting ShhNp mobilization, solubilization and release from the cell membrane (PubMed:22902404, PubMed:22677548). Acts by enhancing the proteolytic processing (shedding) of the lipid-modified N- and C- terminal of ShhNp at the cell surface (PubMed:24522195). Synergizes with DISP1 to increase SHH secretion (PubMed:22902404). Probable cell surface coreceptor for VEGFR2 involved in VEGFR2-mediated angiogenesis (PubMed:27834687)

More Common Targets